AU-007 Immunotherapy for Advanced or Metastatic Cancer
A clinical trial for patients with melanoma, kidney, bladder and other cancers
I'm a Healthcare Professional
A Phase 1/2 study investigating a novel human monoclonal antibody in patients with advanced or metastatic cancer.
About the Clinical Trial
The AU-007 solid tumor study is a first-in-human, open label Phase 1/2 study evaluating the safety, tolerability and immunogenicity of AU-007 in patients with unresectable locally advanced or metastatic cancer. It is enrolling patients at multiple sites in the United States.
Cancer eligibility includes, but is not limited to, skin cancer, renal cell carcinoma, Merkel cell carcinoma, non-small cell lung cancer, gastric cancer and urothelial cancer. Patients who have failed or progressed on anti-PD-1 or anti-PD-L1 therapy may be enrolled in the study.
Who can qualify?
Eligible participants must be 18 years of age and older with refractory or resistant advanced solid tumor cancer who are interested in participating in a clinical trial to evaluate an investigational IL-2 therapeutic.
Where is the study?
The study is enrolling patients at multiple cancer care centers in the U.S. It is being led by seasoned oncologists with expertise in treating advanced cancers and conducting early phase cancer studies.
How does it work?
The Phase 1/2 trial is a two-part, open label, first-in-human study evaluating the safety, tolerability, immunogenicity and clinical activity of AU-007, a computationally designed, human IgG1 monoclonal antibody.